[Experimental study of the therapeutic effect and mechanism of "Shenxian Fuyuan capsule" on chronic renal failure in rats].
OBJECTIVE
To study the therapeutic effect and mechanism of "Shenxian Fuyuan Capsule" (SXFYC) on chronic renal failure in rats with 5/6 nephrectomy.


METHODS
The animal model with chronic renal failure was established by using the method of 5/6 nephrectomy. The animals were randomly divided into four groups: SXFYC treatment group, losartan treatment group, control group and pseudo-operation group (normal group). Since the next day after operations, the rats in the SXFYC treatment group and the losartan treatment group had been intragastrically administrated with SXFYC 300 mg/kg x d and losartan 150 mg/kg x d respectively. The rats in the normal group and control group were fed with sodium chloride twice a day. Four, eight and twelve weeks later, histological and biochemical tests were undertaken to examine changes of the remnant kidney such as alpha-SMA, collagen I, blood urea nitrogen, serum creatinine and proteinuria. The connective tissue growth factor (CTGF) mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).


RESULTS
Both SXFYC and losartan ameliorated the histological change of remnant kidney, decreased the level of CTGF mRNA, serum creatinine and proteinuria (P<0.01). There were no significant differences between the SXFYC and losartan treatment groups (P>0.05).


CONCLUSIONS
"Shenxian Fuyuan Capsule" can improve the renal function of the 5/6 nephrectomized rats. It performs as well as losartan. "Shenxian Fuyuan Capsule" might have played an important role in preventing CTGF-mediated renal fibrosis in the 5/6 nephrectomized rats.
Fu
Ping
P
Division of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China.
He
Cheng-qi
CQ
Liu
Fei
F
Zhou
Li
L
Liu
Fang
F
Tang
Wang-xin
WX
D000818:Animals; D002214:Capsules; D055513:Connective Tissue Growth Factor; D003404:Creatinine / Q000097:blood; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D017874:Immediate-Early Proteins / Q000096:biosynthesis* / Q000235:genetics; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis* / Q000235:genetics; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D008297:Male; D009392:Nephrectomy; D008517:Phytotherapy; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
C526316:CCN2 protein, rat; D002214:Capsules; D004365:Drugs, Chinese Herbal; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D055513:Connective Tissue Growth Factor; D003404:Creatinine